ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.
NEW YORK, April 5, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Shockwave Medical, Inc. (NASDAQ: SWAV) and its board of directors concerning the proposed acquisition of the company by Johnson & Johnson (NYSE: JNJ). Stockholders will receive $335.00 for each share of Shockwave Medical stock that they hold. The transaction is valued at approximately $13.1 billion and is expected to close by mid-2024.
If you are a stockholder of Shockwave Medical, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/swav/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Canopy Growth Corporation ("Canopy Growth" or the "Company") , today announced that on May 2, 2024, it entered into an exchange and subscription agreement (the "Agreement") with a single institutional investor (the "Investor") pursuant to which...
In a heartfelt message in the heart of spring, Kevin Guest, executive chairman at USANA Health Sciences , shares his insights and support for May's Family Wellness Month, an initiative that highlights the importance of family health and unity....
10 Barrel Brewing Co. ("10 Barrel Brewing Co." or "10 Barrel"), a Pacific Northwestern pioneer in craft brewing, a subsidiary of Tilray Brands, Inc. , unveils its latest creation: Pub Cerveza. Building upon the legacy of the ?Cheap Fun.' family,...
Fulgent Genetics, Inc. ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31,...
2seventy bio, Inc. will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET.
Participants can access the conference call live via webcast which will be available...
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC)...
